title: Severe rosacea in a patient on infliximab for ulcerative colitis: pathophysiological considerations.
authors.forename: Maria
authors.initials: M
authors.lastname: Kosmidou
authors.forename: Georgios
authors.initials: G
authors.lastname: Gaitanis
authors.forename: Katon
authors.initials: K
authors.lastname: Nomikos
authors.forename: Aikaterini
authors.initials: A
authors.lastname: Zioga
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Katsanos
authors.forename: Ioannis D
authors.initials: ID
authors.lastname: Bassukas
authors.forename: Epameinondas
authors.initials: E
authors.lastname: Tsianos
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001706:Biopsy; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000627:therapeutic use; D004318:Doxycycline / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000627:therapeutic use; D012393:Rosacea / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D005765:Gastrointestinal Agents; D011433:Propranolol; D000069285:Infliximab; D004318:Doxycycline